Compass Pathways plc - ADR is a clinical-stage biotechnology company focused on mental health care. Compass Pathways develops COMP360, a proprietary synthetic psilocybin therapy being studied for treatment-resistant depression and other psychiatric conditions, including post-traumatic stress disorder and anorexia nervosa. The company’s work centers on evidence-based psychedelic medicine, combining drug development with psychotherapy-oriented treatment models. Based in London, Compass Pathways operates across the United Kingdom and the United States and serves as a specialist participant in the emerging mental health therapeutics market. Its current business is centered on advancing investigational treatments through clinical trials and preparing for broader medical use if approved.